TrialGynecologic oncology2008

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Martee L Hensley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.